1. Home
  2. CF vs GMAB Comparison

CF vs GMAB Comparison

Compare CF & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CF Industries Holdings Inc.

CF

CF Industries Holdings Inc.

HOLD

Current Price

$122.33

Market Cap

18.8B

Sector

Industrials

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$26.89

Market Cap

16.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CF
GMAB
Founded
1946
1999
Country
United States
Denmark
Employees
N/A
3088
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.8B
16.5B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
CF
GMAB
Price
$122.33
$26.89
Analyst Decision
Hold
Strong Buy
Analyst Count
14
8
Target Price
$118.93
$39.56
AVG Volume (30 Days)
2.9M
1.9M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
1.58%
N/A
EPS Growth
33.09
N/A
EPS
3.98
N/A
Revenue
$7,084,000,000.00
N/A
Revenue This Year
$3.85
$17.85
Revenue Next Year
N/A
$16.04
P/E Ratio
$30.63
$1.90
Revenue Growth
19.34
N/A
52 Week Low
$75.42
$20.23
52 Week High
$141.96
$35.43

Technical Indicators

Market Signals
Indicator
CF
GMAB
Relative Strength Index (RSI) 48.76 49.41
Support Level $112.18 $25.34
Resistance Level $131.00 $29.64
Average True Range (ATR) 5.11 0.75
MACD -0.29 0.05
Stochastic Oscillator 51.10 52.21

Price Performance

Historical Comparison
CF
GMAB

About CF CF Industries Holdings Inc.

CF Industries is a leading producer and distributor of nitrogen, which is primarily used in fertilizers. The company operates nitrogen manufacturing plants primarily in North America. CF also produces nitrogen in the United Kingdom and holds a joint venture interest in a nitrogen production facility in Trinidad and Tobago. CF makes nitrogen primarily using low-cost US natural gas as its feedstock, making the company one of the lowest-cost nitrogen producers globally. It is also investing in carbon-free blue and green ammonia, which can be used as an alternative fuel to hydrogen or as a means to transport hydrogen.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: